-
Fosun Pharma Adjusts Investment Allocation for 2022 Non-Public Offering Projects
•
Fosun Pharma (SHA: 600196) has declared adjustments to the investment amounts for some of its non-public offering projects in 2022, including new sub-investment projects. The company plans to reallocate the uninvested funds originally intended for the “API and Preparation Intensive Comprehensive Base” project, amounting to RMB 193.14 million, to another…
-
HutchMed’s Sovleplenib Achieves Primary and Secondary Endpoints in ESLIM-01 Phase III Trial
•
China-based biopharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that the pivotal Phase III trial ESLIM-01 evaluating the investigational use of sovleplenib has successfully met its primary endpoint of durable response rate and all secondary endpoints in adult patients with primary immune thrombocytopenia (ITP). The trial was…
-
Grand Pharmaceutical Group Initiates Phase I Study for Sepsis Treatment APAD
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the enrollment and dosing of the first subject in a Phase I study for APAD, a small-molecule compound targeting sepsis with a novel mechanism of action. The study is a randomized, double-blind, dosage escalation, placebo-controlled trial designed to assess the safety,…
-
HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Gastric Cancer
•
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its MET inhibitor, Orpathys (savolitinib), co-developed with AstraZeneca (AZ, NASDAQ: AZN) and approved in China on July 12, is to be awarded breakthrough therapy designation (BTD) in China. The BTD status is specifically for savolitinib’s use as a third-line treatment…
-
Henan Leads 19-Province Alliance for Volume-Based Drug Procurement Tender
•
A new inter-provincial alliance, led by Henan, has formed a 19-strong group to conduct a volume-based procurement (VBP) tender round for 24 drug specifications. Official price quotes for the tender will be set on August 22, with negotiations scheduled for August 29. Procurement Lists and SpecificationsThe drug varieties are divided…
-
Humanwell Healthcare Initiates Phase IIa Clinical Study for IPF Drug HW021199
•
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced the commencement of a Phase IIa clinical study for its Category 1 chemical drug, HW021199, in the treatment of idiopathic pulmonary fibrosis (IPF). The drug’s target has not been disclosed, other than to note that there is no market-approved product…
-
GSK’s RSV Vaccine Arexvy Launches in US Pharmacies Ahead of 2023/24 Season
•
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has announced that its respiratory syncytial virus (RSV) vaccine, Arexvy, is now available at all major pharmacies in the US. The vaccine received approval in the country earlier this year and was subsequently recommended by the Advisory Committee on Immunization Practices (ACIP)…
-
Eyebright Medical Technology Plans GRD Listing on SIX Exchange to Raise RMB 1.4 Billion
•
Eyebright Medical Technology Co., Ltd (SHA: 688050), a Beijing-based company specializing in ophthalmic medical devices, is poised to issue 8,420,079 Global Depository Receipts (GRDs) on the SIX Exchange, pending approval from the Swiss bourse and regulatory filing in China. The listing is anticipated to generate a take-home amount of RMB…
